Home Headlines Diagnostics firm Bio-Rad in talks to merge with Qiagen – WSJ
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Diagnostics firm Bio-Rad in talks to merge with Qiagen – WSJ

by uma
2 views

(Reuters) -California-based diagnostics company Bio-Rad Laboratories is in talks to merge with Qiagen NV, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Talks between the two companies have been going on for a while but an agreement is unlikely for another few weeks, the report said.

U.S-listed shares of Qiagen rose 8% while Bio-Rad fell nearly 10% after the report.

Bio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market-cap of $12.85 billion.

Both Qiagen and Bio-Rad did not immediately respond to Reuters’ requests for comments.

According to the WSJ report, a deal between the two companies could be worth more than $10 billion, making it one of the biggest in the healthcare testing domain after Illumina Inc’s $8-billion takeover of cancer-testing firm Grail.

Lab equipment supplier Thermo Fisher Scientific in 2020 made a 11.3-billion-euro bid to acquire Qiagen, which fell through after Qiagen shareholders rejected the offer following a hedge fund’s campaign.

(Reporting by Bhanvi Satija in Bengaluru;Editing by Vinay Dwivedi)

 

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More